SET and breast carcinoma: The overexpression of SET suppressed tamoxifen-induced anti-cancer effects and upregulated estrogen receptor element (ERE)-dependent ER signaling transactivation, indicating that SET may be associated with the failure of tamoxifen treatment in ER-positive breast cancer MCF-7 cells (Huang et al. 2018b).